Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population …
T Kerbusch, PA Milligan… - British journal of clinical …, 2004 - Wiley Online Library
Aims To describe the population pharmacokinetic–pharmacodynamic relationship between
darifenacin (UK‐88,525) and its hydroxylated metabolite (UK‐148,993), and the reduction in …
darifenacin (UK‐88,525) and its hydroxylated metabolite (UK‐148,993), and the reduction in …
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population …
T Kerbusch, PA Milligan, MO Karlsson - British Journal of Clinical …, 2004 - elibrary.ru
Aims To describe the population pharmacokinetic-pharmacodynamic relationship between
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic …
T Kerbusch, PA Milligan… - British journal of clinical …, 2004 - pubmed.ncbi.nlm.nih.gov
Aims To describe the population pharmacokinetic-pharmacodynamic relationship between
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
[引用][C] Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population …
T Kerbusch, PA Milligan, MO Karlsson - Br J Clin Pharmacol., 2004 - diva-portal.org
[HTML][HTML] Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population …
T Kerbusch, PA Milligan… - British Journal of Clinical …, 2004 - ncbi.nlm.nih.gov
Aims To describe the population pharmacokinetic–pharmacodynamic relationship between
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic …
T Kerbusch, PA Milligan, MO Karlsson - British Journal of Clinical …, 2004 - europepmc.org
Aims To describe the population pharmacokinetic-pharmacodynamic relationship between
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic …
T Kerbusch, PA Milligan… - British Journal of Clinical …, 2004 - search.ebscohost.com
To describe the population pharmacokinetic–pharmacodynamic relationship between
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
[引用][C] Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population …
T KERBUSCH, PA MILLIGAN… - British journal of …, 2004 - pascal-francis.inist.fr
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its
ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic …
ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic …
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic …
T Kerbusch, PA Milligan, MO Karlsson - British Journal of Clinical …, 2004 - europepmc.org
AIMS: To describe the population pharmacokinetic-pharmacodynamic relationship between
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …
darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in …